Topic:
Chutes and Ladders
Latest Headlines
Latest Headlines
Pfizer sharpens job-cutting ax for U.S. sales layoffs
Pfizer's U.S. sales reps are updating their résumés. The company's primary care sales force faces another round of job cuts, numbers as yet unspecified. The laid-off reps--to be notified Dec. 20, Dow Jones reports--will join thousands of previous patent-cliff casualties.
Gorsky gets it all at J&J, to replace Weldon as chairman
Alex Gorsky now has it all. The CEO of Johnson & Johnson today was named chairman of the drug and consumer products company, replacing Bill Weldon, who is retiring from J&J after four decades.
Targacept taps Stephen A. Hill to serve as president and CEO
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
FDA's Sklamberg promoted to director of CDER's Office of Compliance
Howard Sklamberg, who has been the FDA deputy associate commissioner for regulatory affairs in the Office of Regulatory Affairs (ORA) since July 2011, is stepping up to become director of Center for Drug Evaluation and Research's Office of Compliance.
Sanofi names Gary Nabel chief scientific officer for global R&D
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Teva shunts Americas chief aside in management shuffle
Teva Pharmaceutical Industries ($TEVA) CEO Jeremy Levin, like many newly minted executives, wants to set up his own crew to accomplish his own strategies. So, after about 5 months on the job, he's appointing a new first mate on the generics side.
Bristol-Myers to slash 480 sales-related jobs in NJ
Bristol-Myers Squibb ($BMY) is following up its lackluster third-quarter results with almost 480 layoffs. As Pharmalot reports, the company notified the New Jersey government that it would scale back in Plainsboro, which means the cuts will hit its sales operations.
Eli Lilly appoints Melissa Barnes as chief ethics and compliance officer
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Theratechnologies once again tries to slash its way to breakeven point
Ten months ago, Montreal-based Theratechnologies ($THER) cut its staff, shelved a mid-stage development program and slashed costs, vowing to get on track to profitability in 2013. And that was the second round of layoffs it engineered in 2011.
Aveo slashes workforce, circles wagons around troubled kidney cancer drug
The company's CEO says that 45 staffers are being pink slipped--17% of the workforce--while another 30 open positions will not be filled. The move should save some $100 million over three years.
